Oncolytic virus therapy uses a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed through oncolysis, they release new infectious virus particles that help destroy the remaining tumor. The viruses used are thought not only to cause direct destruction of tumor cells but also to stimulate the host anti-tumor immune system response, and they can affect the tumor microenvironment in multiple ways.
Facts
Origin YearSourced to the subject's own account FAQs
Which oncolytic virus therapy was first approved in the United States?
Talimogene laherparepvec (T-VEC) in October 2015.
On 27 October 2015 the US Food and Drug Administration approved talimogene laherparepvec, known as T-VEC or Imlygic, as the first oncolytic virus therapy. The agency approved it for the treatment of some patients with metastatic melanoma that cannot be surgically removed.
Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
2. Oncolytic Virus (Wikipedia)
WikipediaOncorine (H101) subsection, first two sentences
The first oncolytic virus to be approved by a regulatory agency was a genetically modified adenovirus named H101 by Shanghai Sunway Biotech. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.
https://en.wikipedia.org/wiki/Oncolytic_virus, lead section
An oncolytic virus is a virus that preferentially infects and kills cancer cells.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.